Published in Lab Business Week, January 8th, 2006
The options were granted pursuant to an agreement with an underwriting syndicate co-led by Raymond James, Ltd., and BMO Nesbitt Burns, Inc., and including CIBC World Markets, Inc., and Canaccord Capital Corp. under which the underwriters have agreed to purchase 6,250,000 common shares from AnorMED and sell to the public at a price of $4.00 per common share, representing an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.